Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.58 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14082764 | 0.89 | TRPV1 (0.62) | TRPV1LMNACYP11B2NPC1RAB9A | |
| SCHEMBL14083572 | 0.88 | TRPV1 (0.60) | TRPV1CYP11B2GRM4 | |
| SCHEMBL14083356 | 0.87 | TRPV1 (0.57) | TRPV1TRPV4TP53NPC1RAB9A | |
| SCHEMBL14083575 | 0.87 | TRPV1 (0.62) | TRPV1CYP11B2 | |
| SCHEMBL14083602 | 0.86 | TRPV1 (0.71) | TRPV1MAPTRAB9A | |
| SCHEMBL14083573 | 0.86 | TRPV1 (0.57) | TRPV1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14083213 | 0.86 | TRPV1 (0.53) | TRPV1TRPV4TP53LMNAMAPT | |
| SCHEMBL14083629 | 0.85 | NPC1 (0.58) | TRPV1TP53MAPTCYP11B2NPC1 | |
| SCHEMBL14083595 | 0.85 | TRPV1 (0.79) | TRPV1 | |
| SCHEMBL14083585 | 0.85 | MAPT (0.56) | TRPV1TP53LMNAMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | TRPV1, TRPA1, TRPV2 | TRPV1 1/4885TRPV4 6/4885TP53 4256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.